Skip to Content

'
George R. Blumenschein, Jr., M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 432
Houston, TX 77030
Room Number: FC9.2060
Phone: (713) 792-6363
Fax: (713) 792-1220

Education & Training

Degree-Granting Education

1994 University of Texas Medical School at Houston, Houston, TX, MD, Medicine
1987 Vanderbilt University, Nashville, TN, BA, Political Science

Postgraduate Training

1997-2000 Clinical Fellowship, Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
1994-1997 Clinical Residency, Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX

Selected Publications

Peer-Reviewed Original Research Articles
1. Phan R, Phan L, Ginsberg LE, Blumenschein G, Williams MD, Esmaeli B. Durable response to chemotherapy for recurrent squamous cell carcinoma of the cheek with perineural spread. Arch Ophthalmol 127(8):1074-5, 8/2009. PMID: 19667357.
2. Blumenschein GR, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M. Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. e-Pub 8/2009. PMID: 19652055.
3. Liao ZX, Komaki RR, Thames HD, Liu HH, Tucker SL, Mohan R, Martel MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Influence of Technologic Advances on Outcomes in Patients With Unresectable, Locally Advanced Non-Small-Cell Lung Cancer Receiving Concomitant Chemoradiotherapy. Int J Radiat Oncol Biol Phys. e-Pub 6/2009. PMID: 19515503.
4. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G, Johnson FM, Green S, Gualberto A. Phase II Study of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol 27(15). e-Pub 4/20/2009. PMID: 19380445.
5. Blumenschein G Jr.. Sorafenib in lung cancer: clinical developments and future directions. J Thorac Oncol 3((6 Suppl 2)):S124-7, 6/2008. PMID: 18520294.
6. Lynch TJ Jr, Blumenschein GR Jr, Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, Riely GJ, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A. Summary statement novel agents in the treatment of lung cancer: Fifth cambridge Conference opportunities for combination therapy. J Thorac Oncol 3((6 Suppl 2)):S107-12, 6/2008. PMID: 18520291.
7. Blumenschein GR, Jr., Khuri FR, Pawel J, Gatzemeier U, Miller WH, Jr., Jotte RM, Treut, JL and the GFPC (Groupe Francis Pneumo Cancerologie), Desch C, Sun SL, Zhang JK, Dziewanowska ZE, Vilar AN. A Randomized Phase III Trial Comparing Bexarotene (L1069-48) /Carboplatin/Paclitaxel versus Carboplatin/Paclitaxel in Chemotherapy-Naïve Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (SPIRIT II). J Clin Oncol 26(11):1879-85, 4/2008. PMID: 18398153.
8. Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS, Munden RF, Gladish GW, Herbst RS, Morice RC, Stewart DJ, Jimenez CA, Blumenschein GR Jr, and Onn A. Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer. J Thorac Oncol 3(4):351-7, 4/2008. PMID: 18379352.
9. Husain A, Blumenschein G Jr., Esmaeli B. Treatment and Outcomes for Metastatic Sebaceous Cell Carcinoma of the Eyelid. Int J Dermatol 47(3):276-9, 3/2008. PMID: 18289332.
10. Blumenschein GR, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 26(1):81-7, 2/2008. e-Pub 10/25/2007. PMID: 17960324.
11. Williams MD, Roberts D, Blumenschein GR, Temam S, Kies MS, Rosenthal DI, Weber RS, El-Naggar AK. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol 31(11):1645-52, 11/2007. PMID: 18059220.
12. Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR, Moran C, Allen PK, Komaki R. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys 68(3):779-85, 7/1/2007. e-Pub 4/6/2007. PMID: 17418967.
13. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12(14 Pt 2):4441s-4445s, 7/2006. PMID: 16857825.
14. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Jr, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 7(5):326-31, 3/2006. PMID: 16640804.
15. Lu C, Spitz MR, Zhao H, Dong Q, Truong M, Chang JY, Blumenschein GR, Jr, Hong WK, Wu X. Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer 106(2):441-7, 1/2006. PMID: 16342067.
16. Blumenschein G Jr., Heymach, JV. Angiogenesis Inhibitors for lung Cancer: Clinical developments and future directions. J Thorac Oncol 1(7)(7):744-748, 2006. PMID: 17409952.
17. Robert F, Blumenschein G, Herbst RS, Fossella FV, Tseng J, Saleh MN, Needle M. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 23(36):9089-96, 12/2005. e-Pub 11/2005. PMID: 16301597.
18. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Jr, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104(11):2449-56, 12/2005. PMID: 16258975.
19. Zhongling L, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschein G, Smith CM, Fossella F, Brown B, Cox JD. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 11(9):3342-3348, 5/2005.
20. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23(11):2544-55, 4/2005. e-Pub 3/2005. PMID: 15753462.
21. Tran HT, Blumenschein GR, Jr, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 54(4):308-14, 10/2004. e-Pub 6/2004. PMID: 15184994.
22. Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Jr, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58(5):1369-77, 4/2004. PMID: 15050312.
23. Papadimitrakopoulou VA, Ginsberg LE, Garden AS, Kies MS, Glisson BS, Diaz EM, Jr, Clayman G, Morrison WH, Liu DD, Blumenschein G, Jr, Lippman SM, Schommer D, Gillenwater A, Goepfert H, Hong WK. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer 98(10):2214-23, 11/2003. PMID: 14601092.
24. Johnson FM, Kurie JM, Peeples BO, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park) 17(7 Suppl 7):17-21, 7/2003. PMID: 12886869.
25. Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer 5(1):40-5, 7/2003. PMID: 14596703.
26. Blumenschein GR, Jr, Herbst RS. Integration of targeted therapies in gemcitabine chemotherapy regimens. Clin Lung Cancer 4(4):217-23, 2003. PMID: 14624709.
27. Blumenschein GR Jr, Reckamp K, Stephenson GJ, O'Rourke T, Gladish G, McGreivy J, Sun Y-N, Ye Y, Parson M, Sandler A. Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination With Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non–Small-Cell Lung Cancer. Clin Cancer Res. Submitted.
28. Ross HJ, Blumenschein GR Jr., Aisner J, Damjanov N, Dowlati A, Garst J, Rigas JR, Smylie S, Hassani H, Allen KE, Leopold L, Zaks TZ, Shepherd FA. Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer. Clin Cancer Res. Submitted.

Last updated: 9/10/2009